Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | PARL | Q9H300 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL379296 | 0.78 | PARL (0.34) | ALDH1A1PKMPARLKMT2AATM | |
| SCHEMBL230241 | 0.78 | PARL (0.34) | ALDH1A1PKMPARLKMT2AATM | |
| SCHEMBL9150133 | 0.75 | ALDH1A1 (0.33) | ALDH1A1PKMPARLKMT2AATM | |
| SCHEMBL23801915 | 0.71 | PARL (0.31) | PARL | |
| SCHEMBL28511792 | 0.71 | SMN1; SMN2 (0.37) | ALDH1A1PKMPARLKMT2AATM | |
| SCHEMBL13900968 | 0.67 | PARL (0.31) | PARLKMT2AATM | |
| SCHEMBL11989420 | 0.67 | PARL (0.31) | PARLKMT2AATM | |
| SCHEMBL202493 | 0.67 | ALDH1A1 (0.43) | ALDH1A1PKMKMT2AATM | |
| SCHEMBL18914913 | 0.67 | GLA (0.33) | ALDH1A1KMT2AATM | |
| SCHEMBL57128 | 0.66 | PARL (0.38) | PARLKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1113819-B1 | ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT) WITH GLUCURONIDASE | IMMUNOMEDICS INC (US) | 2011-02-23 | — | — | EP | disclosed |
| US-7470429-B2 | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug | IMMUNOMEDICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20030068322-A1 | Methods of antibody-directed enzyme-prodrug therapy | IMMUNOMEDICS, INC. | 2003-04-10 | — | — | US | disclosed |
| US-20020114808-A1 | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug | IMMUNOMEDICS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6361774-B1 | Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug | IMMUNOMEDICS, INC. | 2002-03-26 | — | — | US | disclosed |
| EP-1113819-A2 | ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (ADEPT) WITH GLUCURONIDASE | Immunomedics, Inc. (US) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000016808-A2 | ANTIBODY DIRECTED ENZYME PRODRUG THERAPY (EDEPT) WITH GLUCORONIDASE | IMMUNOMEDICS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| US-5851527-A | Method for antibody targeting of therapeutic agents | IMMUNOMEDICS, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0294392-B1 | DIAGNOSTIC AND THERAPEUTIC ANTIBODY CONJUGATES | MOLECULAR MEDICINE CENTER (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0505357-A4 | — | — | 1994-03-16 | — | — | EP | disclosed |
| EP-0505357-A1 | METHOD FOR ANTIBODY TARGETING OF DIAGNOSTIC OR THERAPEUTIC AGENTS | IMMUNOMEDICS, INC. (US) | 1992-09-30 | — | — | EP | disclosed |
| US-5057313-A | Diagnostic and therapeutic antibody conjugates | THE CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY (US) | 1991-10-15 | — | — | US | disclosed |
| WO-1991008770-A1 | METHOD FOR ANTIBODY TARGETING OF DIAGNOSTIC OR THERAPEUTIC AGENTS | IMMUNOMEDICS, INC. (US) | 1991-06-27 | — | — | WO | disclosed |
| EP-0294392-A4 | DIAGNOSTIC AND THERAPEUTIC ANTIBODY CONJUGATES. | CT MOLECULAR MED & IMMUNOLOGY (US) | 1989-09-11 | — | — | EP | disclosed |
| EP-0294392-A1 | DIAGNOSTIC AND THERAPEUTIC ANTIBODY CONJUGATES. | MOLECULAR MEDICINE CENTER (US) | 1988-12-14 | — | — | EP | disclosed |
| WO-1987005031-A1 | DIAGNOSTIC AND THERAPEUTIC ANTIBODY CONJUGATES | CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY (US) | 1987-08-27 | — | — | WO | disclosed |